NAMS Stock Overview
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NewAmsterdam Pharma Company N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.09 |
| 52 Week High | US$26.35 |
| 52 Week Low | US$5.63 |
| Beta | 0.081 |
| 1 Month Change | 0.20% |
| 3 Month Change | -3.04% |
| 1 Year Change | 63.33% |
| 3 Year Change | 104.37% |
| 5 Year Change | n/a |
| Change since IPO | 86.02% |
Recent News & Updates
Shareholder Returns
| NAMS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.3% | 3.2% | 1.7% |
| 1Y | 63.3% | 6.0% | 26.3% |
Return vs Industry: NAMS exceeded the US Biotechs industry which returned 7% over the past year.
Return vs Market: NAMS exceeded the US Market which returned 26.1% over the past year.
Price Volatility
| NAMS volatility | |
|---|---|
| NAMS Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NAMS has not had significant price volatility in the past 3 months.
Volatility Over Time: NAMS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 29 | Michael Davidson | www.newamsterdampharma.com |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.
NewAmsterdam Pharma Company N.V. Fundamentals Summary
| NAMS fundamental statistics | |
|---|---|
| Market cap | US$1.80b |
| Earnings (TTM) | -US$228.69m |
| Revenue (TTM) | US$6.86m |
263.2x
P/S Ratio-7.9x
P/E RatioIs NAMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAMS income statement (TTM) | |
|---|---|
| Revenue | US$6.86m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.86m |
| Other Expenses | US$235.55m |
| Earnings | -US$228.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.54 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,332.64% |
| Debt/Equity Ratio | 0% |
How did NAMS perform over the long term?
See historical performance and comparison